ReNeuron Group PLC. Stock Analysis RENE.L

ReNeuron Group Plc engages in the development of novel cell-based therapies that target significant areas of unmet medical need. The company is headquartered in Bridgend, Glamorgan and currently employs 34 full-time employees. The firm is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. The company has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. The company offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.